Please assess the completion status of the following clinical trial:

Trial Title: Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have given written informed consent~* Body mass index (BMI) ≤ 50 kg/m²~* For patients with type 2 diabetes mellitus: either naive of glucose lowering drug or under stable oral glucose lowering drug~* Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73m²~* Liver fat content ≥ 8% on MRI-PDFF~* Qualifying liver biopsy (NAS) ≥ 4 and fibrosis score F1, F2 or F3~* Effective contraception for women of child bearing potential~Exclusion Criteria:~* Evidence of another form of liver disease~* Evidence of liver cirrhosis~* Evidence of hepatic impairment~* Positive serologic evidence of current infectious liver disease~* History of excessive alcohol intake~* Acute cardiovascular disease within 6 months prior to Randomization~* Any disease which in the Investigator's opinion which in the Investigator's opinion would exclude the patient from the study~* Use of non-permitted concomitant medication~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): PXL065 Dose 1
- Group 2 (Type: EXPERIMENTAL): PXL065 Dose 2
- Group 3 (Type: EXPERIMENTAL): PXL065 Dose 3
- Group 4 (Type: PLACEBO_COMPARATOR): Placebo oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).